Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab With Metformin as Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Docetaxel; Metformin; Trastuzumab; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms met-HEReMYTA
- 12 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 12 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 07 Jul 2015 New trial record